Page last updated: 2024-12-10

nvp 231

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	4096211
CHEMBL ID	4303283
CHEMBL ID	4567342
SCHEMBL ID	4252999
MeSH ID	M0528722

Synonyms (35)

Synonym
n-(2-benzamido-1,3-benzothiazol-6-yl)adamantane-1-carboxamide
AKOS001615045
adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)amide
362003-83-6
nvp-231
n-[2-(benzoylamino)-6-benzothiazolyl]-tricyclo[3.3.1.13,7]decane-1-carboxamide
S6501
nvp 231 ,
n-[2-(benzoylamino)-1,3-benzothiazol-6-yl]adamantane-1-carboxamide
gtpl6668
nvp231
MVSSJPGNLQPWSW-UHFFFAOYSA-N
adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)-amide
CS-1808
HY-13945
SCHEMBL4252999
n-[2-(benzoylamino)-6-benzothiazolyl]-tricyclo[3.3.1.1(3,7)]decane-1-carboxamide
n-[2-(benzoylamino)-6-benzothiazolyl]tricyclo[3.3.1.13,7]decane-1-carboxamide
DTXSID40399268
n -[2-(benzoylamino)-6-benzothiazolyl]tricyclo[3.3.1.13,7]decane-1-carboxamide
sr-01000456438
SR-01000456438-1
EX-A709
AS-73454
nvp-231, >=98% (hplc)
mfcd01988824
FT-0700299
Q27088104
BCP15019
n-(2-benzamidobenzo[d]thiazol-6-yl)adamantane-1-carboxamide
CHEMBL4303283
CHEMBL4567342
AC-35988
(3r,5r,7r)-n-(2-benzamidobenzo[d]thiazol-6-yl)adamantane-1-carboxamide
PD063677

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID1345952	Human ceramide kinase (Ceramide kinase)	2008	Molecular pharmacology, Oct, Volume: 74, Issue:4	Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	20.19 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.51 (4.65)
Search Engine Demand Index	15.26 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (20.19)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.1	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	2.05	1	sphing-4-enine	human metabolite; mouse metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.1	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
ceramide 1-phosphate ceramide 1-phosphate : A phosphosphingolipid consisting of any ceramide phosphorylated at position 1. N-octadecanoylsphingosine 1-phosphate : A ceramide 1-phosphate that is the N-octadecananoyl (stearoyl) derivative of sphingosine.	2.05	1	N-acylsphingosine 1-phosphate
n-acetylsphingosine N-acetylsphingosine: inhibits phospholipase D. N-acetylsphingosine : A N-acylsphingosine that has an acetamido group at position 2.	2.05	1	N-acylsphingosine
staurosporine staurosporinium : Conjugate acid of staurosporine.	2.1	1	ammonium ion derivative

Condition	Relationship Strength	Studies
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.04	1
Bone Cancer [description not available]	2.25	1
Breast Cancer [description not available]	2.55	2
Cancer of Lung [description not available]	2.55	2
Invasiveness, Neoplasm [description not available]	2.25	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.25	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.55	2
Lung Neoplasms Tumors or cancer of the LUNG.	2.55	2
Adenocarcinoma, Basal Cell [description not available]	2.1	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.1	1

chemdatabank.com